This site may receive compensation from the provider linked above. Full disclosure.
Local weight loss and GLP-1 providers serving the Flint, Genesee County area, based on Google Business listings.
9468 S Saginaw Rd Suite B, Grand Blanc, MI 48439
(810) 498-2042
5/5 ★ (37 reviews)
Visit website →Residents of Flint, Genesee County can access the full range of FDA-approved GLP-1 receptor agonist medications through Michigan's telehealth framework. Under Michigan Public Act 558 of 2018, licensed physicians may prescribe GLP-1 medications via secure video or asynchronous telehealth consultations — making access for Flint residents faster and more convenient than ever.[1][2]
Michigan has among the highest rates of obesity in the nation at 32.8%, ranking above national average. Michigan's post-industrial landscape includes communities like Detroit, Flint, and Saginaw where economic distress, food deserts, and limited healthcare access have driven obesity rates well above state averages. The Upper Peninsula's remote communities face extreme healthcare access challenges. GLP-1 therapies offer Flint patients a medically supervised, evidence-backed path to meaningful weight loss and improved metabolic health — all without leaving home.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 9, 2026
The most prescribed GLP-1 in Flint. Ozempic® is FDA-approved for type 2 diabetes; Wegovy® is specifically approved for chronic weight management in eligible patients.
The newest dual GIP/GLP-1 receptor agonist available to Flint, Genesee County patients. Zepbound® is FDA-approved specifically for weight loss; Mounjaro® for type 2 diabetes.
A well-established daily GLP-1 option for Flint patients who prefer a gradual, daily-injection approach to chronic weight management.
Getting started with GLP-1 medication in Flint, Genesee County is straightforward. Michigan's telehealth laws allow board-certified physicians to evaluate, prescribe, and manage your treatment entirely online — from your home in Flint.
Fill out a brief, HIPAA-secured medical questionnaire covering your health history, current medications, BMI, and weight management goals. This helps our Michigan-licensed physicians determine your GLP-1 eligibility within 24–48 hours.
A Michigan-licensed, board-certified physician reviews your profile and conducts a personalized telehealth consultation via secure video or asynchronous messaging. They will discuss GLP-1 options, expected outcomes, and any contraindications specific to your health profile.
If approved, your GLP-1 prescription is sent to a licensed US pharmacy. Your medication ships directly to your Flint home address, typically arriving within 3–5 business days in discreet, temperature-controlled packaging.
Your Michigan-licensed provider schedules regular follow-up consultations to monitor your progress in Flint, adjust dosing as needed, and ensure optimal outcomes. Continuous medical oversight is included throughout your GLP-1 treatment.
Michigan has made significant strides in telehealth accessibility. Under Michigan Public Act 558 of 2018, licensed physicians can legally evaluate patients and prescribe medications — including GLP-1 receptor agonists — through secure, HIPAA-compliant telehealth platforms. Residents of Flint, Genesee County are fully covered under this framework.
Michigan has an adult obesity rate of 32.8%, ranking above national average nationally. Genesee County and broader Flint face similar public health challenges, making access to clinically proven GLP-1 medications particularly important for the community. Our telehealth model removes geographical barriers that historically limited access to specialist weight management care across rural and suburban Michigan.
All prescribing physicians in our network hold active Michigan DEA registrations and are board-certified in relevant specialties including endocrinology, internal medicine, or obesity medicine. Every consultation complies with Michigan Medical Board telehealth guidelines.
Our Michigan telehealth providers serve all communities across Genesee County. Explore GLP-1 access in nearby cities within your county.
Residents of cities and communities near Flint can also access GLP-1 telehealth through our licensed Michigan provider network.
Our telehealth platform provides GLP-1 access across all of Michigan. Explore the top cities statewide.
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Complete a short, secure health assessment online. A Michigan-licensed physician will review your profile and consult with you via telehealth within 24–48 hours. If approved, your GLP-1 prescription is sent to a licensed pharmacy and your medication is shipped directly to your Flint address — typically within 3–5 business days.
Yes. Under Michigan Public Act 558 of 2018, licensed physicians can prescribe medications — including GLP-1 receptor agonists — after a proper telehealth evaluation. All prescriptions are issued by Michigan-licensed, DEA-registered physicians through HIPAA-compliant platforms.
Eligible patients in Flint, Genesee County can be prescribed semaglutide (Ozempic®, Wegovy®), tirzepatide (Mounjaro®, Zepbound®), and liraglutide (Saxenda®). Your Michigan-licensed physician will recommend the most appropriate GLP-1 medication based on your individual health profile, BMI, and treatment goals.
Initial eligibility assessments are free. Consultation and medication costs vary by provider and insurance coverage. Many Michigan patients qualify for manufacturer savings programs that significantly reduce out-of-pocket costs. Our team helps identify all available assistance programs during your consultation.
No. The entire process — health assessment, physician consultation, prescription, and medication delivery — is completed online. You never need to visit a clinic, pharmacy, or doctor's office in Flint. Your GLP-1 medication is delivered directly to your home address.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 9, 2026
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
